News & Views
Fungal infections could resist new drug
Sep 07 2011
A team at the University of Aberdeen published their findings for the Society for General Microbiology conference.
They claimed that if the dosage of new drug used to treat Candida albicans is not high enough to start with, the fungus can develop a defence which renders the treatment ineffective.
These findings are important as C.albicans is the most common hospital-acquired infection as it invades the body through plastic such as catheters, cardiac devices or prosthetic joints.
While healthy individuals could fight off the infection, the appearance of the fungus in patients with compromised immune systems could prove fatal.
"If levels of drug are used that do not kill the fungus straight away, C. albicans responds by producing an excess of the other key cell wall sugar polymer, called chitin. Fungal cells displaying higher levels of chitin can survive treatment with echinocandins, allowing infection to progress," said Professor Neil Gow, co-author of the findings.
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK
May 21 2024 Lagos, Nigeria
May 22 2024 Basel, Switzerland